ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) Receives Average Recommendation of “Hold” from Analysts

Share on StockTwits

Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have earned an average recommendation of “Hold” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $6.63.

A number of analysts recently issued reports on ZIOP shares. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $5.50 target price on shares of ZIOPHARM Oncology in a report on Thursday, May 9th. BidaskClub cut ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. Zacks Investment Research upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Raymond James began coverage on ZIOPHARM Oncology in a report on Thursday, August 22nd. They set an “outperform” rating and a $6.50 target price for the company.

Shares of NASDAQ:ZIOP traded down $0.25 during midday trading on Friday, reaching $4.49. 2,365,636 shares of the company’s stock were exchanged, compared to its average volume of 1,806,560. The firm’s 50 day simple moving average is $5.57 and its two-hundred day simple moving average is $4.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. The stock has a market cap of $811.14 million, a price-to-earnings ratio of -9.35 and a beta of 2.73. ZIOPHARM Oncology has a fifty-two week low of $1.56 and a fifty-two week high of $7.25.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). During the same period in the previous year, the business earned ($0.12) earnings per share. Equities research analysts predict that ZIOPHARM Oncology will post -0.34 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of ZIOPHARM Oncology by 24.3% in the 2nd quarter. BlackRock Inc. now owns 11,753,413 shares of the biotechnology company’s stock valued at $68,522,000 after buying an additional 2,294,498 shares during the period. Vanguard Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 11.6% in the 2nd quarter. Vanguard Group Inc. now owns 11,254,728 shares of the biotechnology company’s stock valued at $65,615,000 after buying an additional 1,167,963 shares during the period. Northern Trust Corp lifted its stake in ZIOPHARM Oncology by 3.0% during the second quarter. Northern Trust Corp now owns 1,716,285 shares of the biotechnology company’s stock worth $10,007,000 after purchasing an additional 49,939 shares during the last quarter. Morgan Stanley lifted its stake in ZIOPHARM Oncology by 13.2% during the second quarter. Morgan Stanley now owns 1,385,120 shares of the biotechnology company’s stock worth $8,075,000 after purchasing an additional 161,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in ZIOPHARM Oncology by 7.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 898,615 shares of the biotechnology company’s stock worth $5,239,000 after purchasing an additional 63,762 shares during the last quarter. Institutional investors own 43.19% of the company’s stock.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Recommended Story: Producer Price Index (PPI)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Investment Analysts’ Price Target Changes for October, 14th
Investment Analysts’ Price Target Changes for October, 14th
Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.